Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.109.878611 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spastic cerebral palsy and quality of life in children aged 6-12 years: exploring key associated factors.
Turk J Pediatr
September 2025
Department of Pediatric Neurology, Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Türkiye.
Background: Children with cerebral palsy (CP) may experience epilepsy and challenges with movement, posture, cognition, and musculoskeletal development, which can impact their quality of life (QOL). In this study, we investigated the relationship between demographic and clinical variables as well as QOL in children with spastic CP.
Methods: Children aged 6 to 12 years with CP who were followed-up at our tertiary center were included in this cross-sectional study, regardless of the cause.
Rhabdomyosarcoma in Pediatric Patients Under 2 Years: Clinical Features and Outcome.
J Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDFLong-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.
Neurology
October 2025
Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.
Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).
View Article and Find Full Text PDFImpact of sleep disturbances on health-related quality of life in postmenopausal women: a systematic review.
Menopause
September 2025
Bayer Consumer Care, Basel, Switzerland.
Importance: Sleep disturbances are common during and after the menopause transition, with potential effects on morbidity and quality of life; however, they may be underdiagnosed and undertreated.
Objective: We carried out a systematic literature review to investigate the prevalence and impact of sleep disturbances associated with menopause on women's health-related quality of life across the stages of menopause.
Evidence Review: Searches were conducted in PubMed and Excerpta Medica Database to identify articles published between 2013 and 2023 containing evidence for the impact of sleep quality on health-related quality of life and the epidemiology of sleep disturbances in women in menopause.
Momentum, volume and investor sentiment study for u.s. technology sector stocks-A hidden markov model based principal component analysis.
PLoS One
September 2025
Department of Economics, Cornell University, Ithaca, United States of America.
In this paper, we study the impact of momentum, volume and investor sentiment on U.S. tech sector stock returns using Principal Component Analysis-Hidden Markov Model (PCA-HMM) methodology.
View Article and Find Full Text PDF